NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting

GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 38^th Annual Meeting in San Diego, CA , being held November 1-5, 2023.

“We are pleased that abstracts highlighting recent advances in our AIM injectable program demonstrating the ability to generate broad polyclonal T cell responses from memory and naive populations, as well as the synergistic benefit of a novel IO AIM ACT combination in the oncology setting, have been selected for presentation at SITC 2023,” said Kristi Jones, Chief Executive Officer of NexImmune. “These abstracts showcase the continued advancement of our platform and its therapeutic potential in cancer, autoimmune and infectious diseases.”

Poster Presentation Details:

Title: Efficacy of injectable antigen presenting nanoparticles (AIM INJ), in solid tumor models
Abstract Number: 1139
Category: Poster Presentation
Authors: Haiyun Liu, Duong Nguyen, Durgadas Cherukaraveedu, Adam Parks, Bryan Hahn, Daniel Dembrow, Sojung Kim, Jack Ragheb, Aniket Wadajkar, Mathias Oelke
Date & Time: Friday, Nov. 3, 2023 9 a.m. – 7 p.m. Exhibit Hall A

Title: Enhancement of bispecific T Cell engagers (bispecific TCE) killing potency in AML with NexImmune Artificial Immune Modulation (AIM) Adoptive Cell Therapy (ACT) T cells
Abstract #: 395
Category: Poster Presentation
Authors: Ruipeng Wang, Mathias Oelke, Shweta Jain, Sojung Kim, Jack Ragheb, Adam Parks, Rui Wang, Charles Reed, Brian Alvarez, Jerome Zeldis, Daniel Bednarik
Date & Time: Friday, Nov. 3, 2023 9 a.m. – 7 p.m. Exhibit Hall A

Title: Artificial Immune Modulation (AIM) nanoparticles expand antigen specific CD8 T cells from both naïve and memory T cell populations
Abstract #: 396
Category: Poster Presentation
Authors: Ruipeng Wang, Lauren Suarez, Bryan Hahn, Alison Farrell, Sojung Kim and Mathias Oelke
Date & Time: Saturday, Nov. 4, 2023 9 a.m. – 8:30 p.m. Exhibit Hall A

All posters presented at the poster hall will be made available as virtual ePosters throughout the SITC 38th Annual Meeting.

About NexImmune

NexImmune is developing novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities. NexImmune is focused on developing injectable AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology, autoimmune disorders and infectious diseases.